ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

Lithuania donates COVID-19 vaccines to Taiwan

Move to ship 20,000 doses likely to anger China further

A medical worker administers a dose of the AstraZeneca vaccine against COVID-19 to a man during a vaccination session for elderly people over 85 years old, at an auditorium in New Taipei City on June 16.   © Reuters

VILNIUS (Reuters) -- Lithuania will donate 20,000 doses of AstraZeneca Plc COVID-19 vaccine to Taiwan, its government said on Tuesday, after angering China in March by saying it would open a trade representative office on the island this year.

China considers Taiwan its own territory.

The vaccines were donated after a June 15 request for help from Taipei's mission in neighbouring Latvia, the Lithuanian health ministry said in a submission to the government. They will be transferred by the end of September.

"We'd like to do more, but we do what we can," Prime Minister Ingrida Simonyte said during a government meeting that was broadcast in Lithuania.

Taiwan President Tsai Ing-wen's spokesman Xavier Chang office hailed the donation, adding: "This friendship from the Baltic Sea is precious."

Taiwan had given Lithuania 100,000 medical-grade face masks last year when the coronavirus pandemic was spreading around the world, he said.

Taiwan is trying to speed up a vaccination programme that has been hobbled by supply delays.

It got a major boost this month when Japan donated 1.24 million AstraZeneca shots, followed on Sunday by 2.5 million Moderna Inc doses from the United States.

Infection numbers are now falling on the island after a rise since last month.

Lithuania's government said last month it would also donate 100,000 vaccine doses to Ukraine, 15,000 to Georgia and 11,000 to Moldova.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more